- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ibuprofen Safest NSAID for Patients with Chronic Kidney Disease, claims study

Both over-the-counter and prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used all over the world. In a recent study, researchers have reported that the NSAIDs increases the risks for an incident estimated glomerular filtration rate (eGFR, in mL/min/1.73 m2) below 60 and an eGFR decline of 30% or greater. They also found that ibuprofen is comparatively safer than etoricoxib for patients with CKD. The study findings were published in the Clinical Journal of the American Society of Nephrology on April 28, 2021.
Although NSAIDs are commonly used for the management of inflammation and pain, several guidelines including, the Kidney Disease Initiative Global Outcome (KDIGO) guidelines, recommended avoidance of NSAIDs (except aspirin and acetaminophen) for most patients with chronic kidney disease (CKD). The difference between risks of individual nonsteroidal anti-inflammatory drugs also remains unclear. Therefore, researchers of the University of Hong Kong conducted a study to evaluate the association between NSAID exposure and the risk of incident eGFR <60 ml/min per 1.73 m2 and compare the risks between nonsteroidal anti-inflammatory drug subtypes in the Chinese population.
It was a retrospective study of 1,982,488 subjects aged 18 years or older with baseline eGFR ≥60 ml/min per 1.73 m2. The researchers used multivariable Cox proportional hazards regression adjusted for each patient's baseline characteristics to examine the association between nonsteroidal anti-inflammatory drug and incident eGFR <60 ml/min per 1.73 m2 or eGFR decline ≥30% with baseline reference.
Key findings of the study were:
- After a median follow-up duration of 6.3 years, the researchers identified 14% of incident eGFR <60 ml/min per 1.73 m2 and 21% events of eGFR decline ≥30%.
- After adjusting for each patient's baseline characteristics, they found that NSAIDs significantly increases the risk of incident eGFR <60 ml/min per 1.73 m2 (hazard ratio, 1.71) and eGFR decline ≥30% (HR1.93) when compared with no NSAID.
- They noted that among NSAIDs, etoricoxib exhibited the highest risk of eGFR<60 ml/min per 1.73 m2 (HR, 3.12) and eGFR decline ≥30% (HR, 3.11) and ibuprofen displayed the lowest risk of eGFR<60 ml/min per 1.73 m2 (HR, 1.12) and eGFR decline ≥30% (HR, 1.32).
The authors concluded, "Nonsteroidal anti-inflammatory drug exposure was associated with higher risks of incident eGFR <60 ml/min per 1.73 m2 and eGFR decline ≥30%. Highest risk was observed in etoricoxib users, and lowest risk was with ibuprofen."
For further information:
Dr Kartikeya Kohli, Senior Consultant in Internal Medicine and specialist in Diabetes,Obesity and kidney diseases has done his DNB (Medicine), MRCP (UK). He has also obtained ECFMG Certification from USA in 2011. Also he has done his super-specialist training in Nephrology at IP Apollo Hospital. Dr Kohli is currently practicing as Consultant Internal Medicine at Sitaram Bhartia Institute of Science and Research and Apollo Clinic in East of Kailash. In the past, he has worked with several renowned hospitals in Delhi, including Apollo Hospital, Sir Ganga Ram Hospital & Fortis Vasant kunj. His additional academic qualifications include a PG Diploma in Clinical Endocrinology & Diabetes, Advanced Diabetes Care & Comorbidities, and Advanced Cardiology & ECG from the Royal College of Physicians. Dr Kohli has made significant contributions to medical academics and professional education. He has independently organised more than 100 Continuing Medical Education (CME) programmes and authored over 200 medical articles for various medical bulletins and healthcare portals, including Medical Dialogues.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

